{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:36:49Z","timestamp":1769755009293,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T00:00:00Z","timestamp":1401926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec>\n                    <jats:title>Study Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate real\u2010world clinical and economic outcomes in patients with\n                      <jats:italic>Clostridium difficile<\/jats:italic>\n                      infection (\n                      <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>\n                      ) treated with fidaxomicin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Academic medical center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>\n                      A total of 61 patients with\n                      <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>\n                      who were treated with fidaxomicin monotherapy or combination therapy from September 2011 to December 2012.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>\n                      Data on demographics, infection characteristics, and clinical and economic outcomes were evaluated. Clinical cure was defined as resolution of diarrhea (less than or equal to three unformed stools for at least 2 consecutive days) maintained for the duration of therapy with no further requirement for\n                      <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>\n                      therapy and was achieved in 44 (72.1%) patients. Clinical cure was significantly higher for patients receiving fidaxomicin monotherapy compared with fidaxomicin combination therapy (25\/29 [86.2%] patients vs 19\/32 [59.4%] patients, p=0.04). Clinical cure was similar in patients with a first or prior\n                      <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>\n                      episode (65.5% vs 78.1%, p=0.27) and in patients with severe versus nonsevere disease (68.4% vs 73.8%, p=0.66). Recurrence occurred in 6 (13.6%) of the 44 patients who achieved clinical cure. Mortality attributable to\n                      <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>\n                      was 11.5%, and 30\u2010day readmission rate was 4.9%. Median cost accrued during\n                      <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>\n                      was $19,483\/patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our real\u2010world experience with fidaxomicin significantly differs from the findings of phase III clinical trials. Fidaxomicin is also associated with substantial costs. Multicenter studies are needed to determine the optimal role of fidaxomicin in the treatment of\n                      <jats:styled-content style=\"fixed-case\">CDI<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.1451","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T01:23:31Z","timestamp":1401931411000},"page":"901-909","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["An Antimicrobial Stewardship Program's Real\u2010World Experience with Fidaxomicin for Treatment of\n                    <i>Clostridium difficile<\/i>\n                    Infection: A Case Series"],"prefix":"10.1002","volume":"34","author":[{"given":"Craig A.","family":"Vargo","sequence":"first","affiliation":[{"name":"Department of Pharmacy The Ohio State University, Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karri A.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Ohio State University, Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie E.","family":"Mangino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Division of Infectious Diseases The Ohio State University, Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica E.W.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Division of Infectious Diseases The Ohio State University, Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra A.","family":"Goff","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Ohio State University, Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/651706"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/588756"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1309.061116"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051639"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050978"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1407.070867"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/338260"},{"key":"e_1_2_6_9_1","unstructured":"GoffDA WestJE BauerKA ManginoJE.An antimicrobial stewardship economic analysis of Clostridium difficile infections (CDI). 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) London UK March 31 \u2010 April 3 2012. [Unpublished Work]"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/526530"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/522676"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.9763"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.28"},{"key":"e_1_2_6_14_1","unstructured":"Antibiotic resistance threats in the United States. Available fromhttp:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. Accessed October 12 2013."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/510393"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2164"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6701(92)90092-Z"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.5.813"},{"key":"e_1_2_6_19_1","first-page":"168","article-title":"Drug evaluation: OPT\u201080, a narrow\u2010spectrum macrocyclic antibiotic","volume":"2","author":"Johnson AP","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2280-2282.2004"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4430-4434.2004"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4898-4902.2004"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-06"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00476-08"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90129-5"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2007.09.015"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/658336"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.03099.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis462"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/501126"},{"key":"e_1_2_6_33_1","unstructured":"Medi\u2010Span Price Rx. Available fromhttps:\/\/pricerx.medispan.com\/. Accessed August 15 2013."},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.11.004"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit346"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1451","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:18:43Z","timestamp":1761067123000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,5]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1002\/phar.1451"],"URL":"https:\/\/doi.org\/10.1002\/phar.1451","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,5]]},"assertion":[{"value":"2014-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}